The Tufts spinout has not identified any of its investors in the round, which will go towards the launch of a feed additive to prevent avian livestock infections.

The autoimmune drug developer has received $4.6m from Boehringer Ingelheim Venture Fund to take its series A round to $20.8m.

Abbvie and Mitsubishi Tanabe Pharma participated in the RNA therapy startup's first round through their corporate venturing units.

Exicure has added an $11.2m private placement led by Luye Pharma to the $20.1m it raised from investors including AbbVie last month.

ADCendo will develop a single oncology therapy combining antibodies with cytotoxic drugs used during chemotherapy.

Northwestern University spinout Exicure, formerly known as AuraSense Therapeutics, has added $11.2m to its latest funding round with contributions from Purple Arch Ventures.

Topas has closed its series A round at nearly $21m, following a $4.6m extension that will be used to advance potential autoimmune disease therapies towards clinical trials.

The bacterial infections drug developer, based on research at Harvard Medical School, has gone public.

The bacterial infections drug developer, backed by Alphabet, Partners Healthcare, GlaxoSmithKline, Merck & Co and Lundbeck, has gone public.